Results 221 to 230 of about 32,467 (248)
Some of the next articles are maybe not open access.
Moxifloxacin: a respiratory fluoroquinolone
Expert Opinion on Pharmacotherapy, 2008Respiratory quinolones are a class of antimicrobials with a high activity against most respiratory pathogens. Moxifloxacin is a fourth-generation fluoroquinolone that has been shown to be effective against Gram-positive, Gram-negative, and atypical strains, as well as multi-drug resistant Streptococcus pneumoniae.To review and update the clinical ...
Marc, Miravitlles, Antonio, Anzueto
openaire +2 more sources
Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin
Drug Safety, 2009Moxifloxacin, a fluoroquinolone with potent activity against respiratory pathogens, is approved and considered as an alternative to beta-lactams and macrolides for the treatment of acute bacterial sinusitis and lower respiratory tract infections. In this review, we critically examine its safety profile in comparison with other fluoroquinolones and ...
Françoise, Van Bambeke, Paul M, Tulkens
openaire +2 more sources
Use of fluoroquinolones in lower respiratory tract infections (LRTI)
International Journal of Antimicrobial Agents, 1994In view of their antimicrobial activity and pharmacological properties, fluoroquinolens should be suitable for the treatment of lower respiratory tract infections - specially of Gram-negative bacterial etiology. These drugs have been studied extensively in animal models of respiratory tract infections and found to be as efficacious as the comparative ...
H, Lode +3 more
openaire +2 more sources
[Fluoroquinolones in respiratory infections].
Presse medicale (Paris, France : 1983), 1995Given orally, currently marketed fluoroquinolones, ciprofloxacin, ofloxacin and pefloxacin are absorbed rapidly, have an excellent diffusion coefficient. They are wide-spectrum first intention antibiotics effective against Gram negative bacilli, staphylococci and intracellular germs such as Legionella, Chlamydiae and mycoplasms.
Y, Mouton, O, Leroy
openaire +1 more source
Microbiology of newer fluoroquinolones: focus on respiratory pathogens
Diagnostic Microbiology and Infectious Disease, 2002Community-acquired pneumonia, acute exacerbations of chronic bronchitis, and acute sinusitis are among the most common bacterial infections encountered in clinical practice. Pathogens frequently associated with these infections include Streptococcus pneumoniae, Hemophilus influenzae, Moraxella catarrhalis, Chlamydia pneumoniae, Legionella pneumophila ...
openaire +2 more sources
Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections
Annals of Pharmacotherapy, 2004OBJECTIVE: To evaluate the microbiology, pharmacokinetic parameters, drug interactions, and results of the available clinical trials of gemifloxacin for the treatment of community-acquired pneumonia (CAP) and acute exacerbation of chronic bronchitis (AECB). DATA SOURCES: MEDLINE (1966–September 2003) was searched for primary and review articles.
Bong K, Yoo +3 more
openaire +2 more sources
Evaluation and cost assessment of fluoroquinolones in community-acquired respiratory infections
Expert Opinion on Pharmacotherapy, 2002Several new fluoroquinolones have been marketed since the late 1990s. Fluoroquinolones are an effective treatment for most community-acquired respiratory tract infections, including acute sinusitis, acute exacerbations of chronic bronchitis and community-acquired pneumonia.
Steven J, Martin +2 more
openaire +2 more sources
Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections
Current Opinion in Pharmacology, 2001High occurrence of penicillin-resistant and multidrug-resistant Streptococcus pneumoniae and reports of resistance with Haemophilus influenzae and Moraxella catarrhalis are influencing the empiric treatment of community-acquired respiratory infections and allowing the new fluoroquinolones to serve as important treatment alternatives. Recent analysis of
G G, Zhanel, A M, Noreddin
openaire +2 more sources
Highlights on the appropriate use of fluoroquinolones in respiratory tract infections
Pulmonary Pharmacology & Therapeutics, 2006The impact of respiratory infections on public health is increasing, and lower respiratory tract infections are a major cause of morbidity and mortality. Moreover, most antibiotic prescriptions are related to respiratory infections and this is probably one of the main determinants of the increasing rate of bacterial resistance in both community and ...
F. Blasi +4 more
openaire +3 more sources
The role of fluoroquinolones in respiratory tract infections: community acquired pneumonia
International Journal of Antimicrobial Agents, 2000Newer fluoroquinolones may play an important role in the management of community acquired pneumonia. They retain activity similar to older fluoroquinolones against Gram-negative bacteria and are significantly more active against Gram-positive bacteria, especially pneumococci.
J A, García-Rodríguez +1 more
openaire +2 more sources